KIMBERLY BROWN: Open Payments
NPI 1508934035 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$157,021 in 69 payments from 9 companies in 2025. Trend: 2023 $130,432 · 2024 $133,894 · 2025 $157,021
Speaker / faculty: $104,847Consulting: $38,670Travel & lodging: $6,485Speaker / faculty: $4,960Food & beverage: $2,060
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 21 | $45,482 |
| Gilead Sciences, Inc. | 24 | $45,218 |
| Mallinckrodt Hospital Products Inc. | 8 | $29,109 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $20,440 |
| Intercept Pharmaceuticals, Inc. | 4 | $7,339 |
| Ipsen Biopharmaceuticals, Inc | 1 | $4,590 |
| GlaxoSmithKline, LLC. | 1 | $4,000 |
| Bausch Health US, LLC | 1 | $800 |
| Boston Scientific Corporation | 2 | $44 |
Products named: REZDIFFRA, TERLIVAZ, Livdelzi, Epclusa, XIFAXAN, OCALIVA, Vemlidy, IQIRVO.
Industry payments across MI — which companies pay providers there.
